Scemblix Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Asciminib

Indications/Uses

Adult patients w/ Philadelphia chromosome +ve chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated w/ ≥2 tyrosine kinase inhibitors. Ph+ CML in CP harboring T315I mutation.

Dosage/Direction for Use

Ph+ CML-CP Total daily dose: 80 mg, taken either as 80 mg once daily at approx same time each day or 40 mg bd at approx 12 hr intervals. Ph+ CML-CP harboring T315I mutation 200 mg bd at approx 12 hr intervals.

Administration

Should be taken on an empty stomach: Avoid food consumption for at least 2 hr before & 1 hr after. Swallow whole, do not break/crush/chew.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EA06 - asciminib ; Belongs to the class of BCR-ABL tyrosine kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Scemblix FC tab 20 mg

Packing/Price

1's

Form

Scemblix FC tab 40 mg

Packing/Price

1's

Scemblix

Manufacturer:

Novartis Pharma Stein